# Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer

> **NCT02676986** · PHASE2 · COMPLETED · sponsor: **Queen Mary University of London** · enrollment: 221 (actual)

## Conditions studied

- Primary Breast Cancer ER+ve
- Primary Breast Cancer AR+ve TNBN

## Interventions

- **DRUG:** Enzalutamide
- **DRUG:** Exemestane

## Key facts

- **NCT ID:** NCT02676986
- **Lead sponsor:** Queen Mary University of London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-10
- **Primary completion:** 2016-12-31
- **Final completion:** 2016-12-31
- **Target enrollment:** 221 (ACTUAL)
- **Last updated:** 2024-07-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02676986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02676986, "Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02676986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*